Related Experiment Videos
Improved outcomes with antihypertensive medication in the elderly with isolated systolic hypertension
1Study Coordinating Center, Department of Molecular and Cardiovascular Research, University of Leuven, Belgium.
Insights
Isolated systolic hypertension in older adults significantly increases cardiovascular risk. Antihypertensive drug treatment is proven effective and justified for patients with systolic blood pressure (SBP) of 160 mm Hg or higher.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Clinical Pharmacology
Background:
- Isolated systolic hypertension (ISH) affects over 15% of individuals over 60.
- ISH is a significant, modifiable cardiovascular risk factor in the elderly.
- Pulse pressure is a key risk factor, with SBP linked to adverse outcomes and DBP inversely correlated with mortality.
Purpose of the Study:
- To evaluate the efficacy of antihypertensive drug treatment in older patients with ISH.
- To provide evidence-based recommendations for managing ISH in the elderly population.
Main Methods:
- Meta-analysis pooling data from three major placebo-controlled trials (SHEP, Syst-Eur, Syst-China) and subsets from five other elderly trials.
- Inclusion of 15,693 older patients diagnosed with isolated systolic hypertension.
Main Results:
- Antihypertensive drug treatment demonstrated significant benefits in reducing adverse outcomes for elderly patients with ISH.
- Pooled results confirm the efficacy of pharmacological intervention for ISH.
Conclusions:
- Antihypertensive drug treatment is clinically justified for older individuals with isolated systolic hypertension when systolic blood pressure is consistently 160 mm Hg or higher.
- This evidence supports the initiation of treatment to mitigate cardiovascular risks associated with ISH in the elderly.
Abstract:
Isolated systolic hypertension affects over 15% of all individuals aged >60 years. In the elderly, systolic hypertension is a major modifiable cardiovascular risk factor. Systolic blood pressure (SBP) is associated with higher risk of an adverse outcome, whereas diastolic blood pressure (DBP) is inversely correlated with total mortality, independent of SBP, highlighting the role of pulse pressure as a risk factor. Three placebo-controlled outcome trials on antihypertensive drug treatment in older patients with isolated systolic hypertension have been published: the Systolic Hypertension in the Elderly Program (SHEP), the Systolic Hypertension in Europe (Syst-Eur) Trial and the Systolic Hypertension in China (Syst-China) Trial. These 3 trials demonstrated the benefit of antihypertensive drug treatment. A meta-analysis was performed by pooling the patients from these 3 trials with a subset of patients with isolated systolic hypertension from 5 other trials in the elderly. The pooled results of 15,693 older patients with isolated systolic hypertension prove that antihypertensive drug treatment isjustified if on repeated clinic measurements SBP is 160 mm Hg or higher.